(WASHINGTON, D.C.) — Following promises made by President Donald Trump that Americans would see a COVID-19 vaccine as soon as Election Day, the CEO of Pfizer, Albert Bourla has refuted those claims.

Bourla noted that the Data Monitoring Committee, which is overseeing clinical studies and data collection of all vaccine candidates, “has not conducted any interim efficacy analyses to date,” so it is unlikely a vaccine will be made readily available by November 3.

Bourla added that Pfizer has submitted an application for authorization, which is on track to be approved next month.   He added that the company “may know whether or not our vaccine is effective by the end of October.”

The trial currently underway has 32 volunteers infected with the novel coronavirus who will be separated into two groups, one who will receive a placebo and the other will be given the vaccine.

The vaccine will be deemed successful if roughly 77 percent of the infected is found among the placebo group and, should that be the case, the company will seek emergency use authorization.

Should Pfizer not reach that number of over 76.9 percent, more trials will be run.

Bourla admitted he is “cautiously optimistic” regarding the vaccine the company developed, basing his opinion on earlier studies.  He also added that the vaccine will not be hindered by partisan efforts, vowing, “This will not be a Democratic vaccine or Republican vaccine; this will be a vaccine for the world.”

Currently, there are 150 vaccine candidates being developed worldwide.

COVID-19 has infected nearly 8.8 million Americans and has killed more than 226,000.